Drug intelligence / Profile preview

Smoflipid (Fresenius Kabi)

Development stage
Approved
Lead developer
Fresenius Kabi
Modality
Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Intravenous, Parenteral
01

Overview

Smoflipid is a sterile, nonpyrogenic, white, homogenous lipid injectable emulsion developed and marketed by Fresenius Kabi. It is a four-oil blend comprising soybean oil (6%), medium-chain triglycerides (6%), olive oil (5%), and fish oil (3%), providing a total lipid content of 0.2 g/mL. Smoflipid is indicated in adult and pediatric patients, including term and preterm neonates, as a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. The formulation delivers a balanced mixture of essential and non-essential fatty acids, including omega-3 fatty acids (EPA and DHA), which support energy metabolism, cellular structure, and immune function while minimizing the risk of lipid peroxidation and parenteral nutrition-associated liver disease.

Brand names
SMOFLIPID
Other names
fat emulsionintravenous lipid emulsionlipid injectable emulsionlipid injectable emulsion, USP 20%

Beyond the preview

Go deeper on Smoflipid (Fresenius Kabi).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Smoflipid (Fresenius Kabi).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call